Redmile Group’s Immunic IMUX Stock Holding History

Redmile Group’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,738	Closed	-$7.5M	–	88
2018 Q2	$7.5M	Buy	+2,738	New	+$6.33M	0.25%	56

Other funds holding IMUX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Redmile Group's IMUX Position: Q3 2018 in Review

Redmile Group sold out of Immunic (IMUX) in Q3 2018, closing a stake of 2,738 shares — an estimated $7.5M sold.

Redmile Group first reported a position in IMUX in Q2 2018 and held it in 1 quarter. The position peaked at $7.5M in Q2 2018. 54 funds tracked by Wall St. Rank hold IMUX as of Q3 2018.

Redmile Group reported no remaining Immunic position as of Q3 2018 after selling out during the quarter.
Redmile Group sold 2,738 Immunic shares in Q3 2018, an estimated $7.5M.
Redmile Group first reported a position in Immunic in Q2 2018 and held it in 1 quarter.
Redmile Group's Immunic position peaked at $7.5M in Q2 2018.
54 funds tracked by Wall St. Rank held Immunic as of Q3 2018.

Based on Redmile Group's 13F filing for Q3 2018, filed 14 Nov 2018.